ROCHESTER, Minn. — A Mayo Clinic-led group of researchers has discovered three subgroups of a single type of non-Hodgkin lymphoma that have markedly different survival rates. These subgroups could not be differentiated by routine pathology but only with the aid of novel genetic tests, which the research team recommends giving to all patients with ALK-negative anaplastic large-cell lymphoma (ALCL). Findings are published in the journal Blood.
Recent Posts
- CAR NK cell therapy clinical trial puts follicular lymphoma survivor into remission
- Stem cell therapy linked to lower risk of heart failure after a heart attack
- Embryo-Like ‘Blood Factories’ Could One Day Supplement Donations
- Long-Term Growth Hormone Therapy Boosts Pediatric Stem Cells
- New UCLA drug could restore heart and organ function
- Parkinson’s treatment tested at UW showing promise in first clinical trial

